Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea | NCT01976624 | Trialant
CompletedObservationalUpdated Sep 28, 2015
Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea
ClinicalTrials.gov ID
NCT01976624
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Observational
Enrollment
756Actual
Last Update Posted
Sep 28, 2015Estimated
Start Date
Aug 2009
Primary Completion Date
Jan 2014Actual
Completion Date
Jan 2014Actual
Brief Summary
This study is a Post-Marketing Surveillance study to evaluate the safety and efficacy of bimatoprost/timolol (Ganfort®) Ophthalmic Solution to treat open-angle glaucoma or ocular hypertension in Korea.
Glaucoma, Open-Angle
Ocular Hypertension
bimatoprost/timolol
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients treated with Ganfort® for open-angle glaucoma or ocular hypertension in clinical practice.